Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.
OBJECTIVE
This study analyses the risk of cardiac complications and its individual predictability in bone marrow transplantation (BMT).


METHODS
One hundred seventy patients undergoing allogeneic (n = 150) or autologous (n = 20) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 3 months thereafter.


RESULTS
Following BMT, cardiac toxicity occurred in eight patients (4.7%). Three patients (1.8%) developed life-threatening toxicity (pericardial effusion and left ventricular failure, n = 2; sudden cardiac arrest, n = 1). Thirty-eight patients (22%) had pathologic findings before BMT. In 22 patients, left ventricular ejection fraction (EF) determined by RNV was reduced to less than 55%. This was the only abnormality in 17 patients and was generally mild, with a lowest EF of 42%. There was no correlation between overall results of cardiologic evaluation before BMT and cardiac toxicity. Cardiotoxic events occurred more frequently in patients with a reduced EF (P < .05). However, this was restricted to minor cardiac events. Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before BMT. Moreover, none of the patients with an EF less than 50% developed cardiac toxicity.


CONCLUSIONS
Life-threatening cardiac toxicity is rare after BMT, occurring in less than 2% of all patients. Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients.
Hertenstein
B
B
Department of Internal Medicine III (Hematology and Oncology), University of Ulm, Germany.
Stefanic
M
M
Schmeiser
T
T
Scholz
M
M
Göller
V
V
Clausen
M
M
Bunjes
D
D
Wiesneth
M
M
Novotny
J
J
Kochs
M
M
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003131:Combined Modality Therapy; D005260:Female; D006321:Heart / Q000502:physiology*; D006323:Heart Arrest / Q000209:etiology; D006331:Heart Diseases / Q000209:etiology*; D006333:Heart Failure / Q000209:etiology; D006334:Heart Function Tests; D006402:Hematologic Diseases / Q000628:therapy; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010490:Pericardial Effusion / Q000209:etiology; D011237:Predictive Value of Tests; D012306:Risk; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents